GlassScriptPhysician profile
Morgan Hammock
NPI 1902104870
$420.24
in general payments reported to CMS, 2019-2025
13 companies · $94.65 in 2025
The $94.65 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.94 · 2022: $19.40 · 2023: $60.25 · 2024: $168 · 2025: $94.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $77.26 | 2024 | Pico, Renasys Touch, Collagenase Santyl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.25 | 2023 | Trulance, Xifaxan |
| Organogenesis INC. | $51.49 | 2024-2025 | Puraply Wound Matrix |
| Paratek Pharmaceuticals, INC. | $38.90 | 2024 | Nuzyra |
| Janssen Pharmaceuticals, INC | $28.06 | 2021 | |
| Abbvie INC. | $26.40 | 2021 | |
| Hartmann USA, INC. | $25.00 | 2025 | Zetuvit Plus 10x10 P10 |
| Novo Nordisk INC | $23.48 | 2021 | |
| Solventum Corporation | $20.03 | 2025 | Activ.A.C. |
| Kowa Pharmaceuticals America, INC. | $19.40 | 2022 | |
| Ossur Americas, INC. | $17.67 | 2025 | |
| Kerecis Limited | $17.61 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Lilly USA, LLC | $14.69 | 2024 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Hammock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.